Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ioneer Ltd (PK) | USOTC:GSCCF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.001 | 1.25% | 0.081 | 0.0687 | 0.1039 | 0.089 | 0.081 | 0.089 | 12,309 | 22:00:01 |
Exhibit
|
Description
|
|
Notice of Annual Meeting 2023
|
ioneer Ltd
|
|||
(registrant)
|
|||
Date: September 28, 2023
|
By:
|
/s/ Ian Bucknell |
Name:
|
Ian Bucknell | |
Title:
|
Chief Financial Officer & Company Secretary |
Date
|
3 November 2023
|
Time
|
10:00AM (AEDT)
|
IMPORTANT NOTICE:
The 2023 Annual General Meeting (AGM or meeting) of shareholders of ioneer Limited (ABN 76 098 564 606) (the "Company") will be held on Friday, 3 November 2023 at 10:00AM (AEDT). Shareholders are invited to attend the AGM at the Vibe Hotel North Sydney, 171 Pacific Highway, North Sydney NSW 2060 and online at https://web.lumiagm.com/349221399. Details about how shareholders can participate in the meeting are included over the page.
|
Meeting ID: 349-221-399
|
|
Australian Residents
|
1. Username – Voting Access Code (VAC)
Your VAC can be located on your personalised Proxy Form or on your Notice of Meeting email.
2. Password
This is the postcode of your registered address.
|
Overseas Residents
|
1. Username – Voting Access Code (VAC)
Your VAC can be located on your personalised Proxy Form or on your Notice of Meeting email.
2. Password
Three-character country code e.g. New Zealand – NZL.
|
Proxyholders
|
To receive you Username and Password, please contact our share registry, Boardroom Pty Ltd on 1300 737 760 or +61 2 9260 9600 between 8.30AM and 5.30PM (AEDT)
Monday to Friday before the meeting.
|
1. |
Financial Statements and Reports
|
2. |
Remuneration Report
|
• |
by or on behalf of a member of the Company’s Key Management Personnel (KMP), details of whose remuneration is disclosed in the Remuneration Report for the year ended 30 June 2023 and their
closely related parties, regardless of the capacity in which the vote is cast; or
|
• |
as proxy of a KMP at the date of the AGM and their closely related parties.
|
• |
in accordance with the directions on the proxy form; or
|
• |
by the Chairman of the AGM in accordance with an express authorisation in the proxy form to exercise the proxy even though the resolution is connected directly or indirectly with the remuneration of a KMP.
|
3. |
Re-election of Directors
|
4. |
Approval of issue of Performance Rights to Directors in lieu of Directors’ fees
|
• |
Resolution 4(a) by James D. Calaway or any of his associates;
|
|
• |
Resolution 4(b) by Alan Davies or any of his associates;
|
• |
Resolution 4(c) by Stephen Gardiner or any of his associates;
|
• |
Resolution 4(d) by Rose McKinney-James or any of her associates; and
|
• |
Resolution 4(e) by Margaret R. Walker or any of her associates.
|
• |
it is cast in favour of a resolution by a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way;
|
• |
it is cast by the Chairman of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the Chairman to vote on the resolution as the Chairman decides; or
|
• |
it is cast by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
|
o |
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on the resolution; and
|
o |
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
|
5. |
Approval of Grant of Performance Rights to Bernard Rowe
|
• |
it is cast in favour of a resolution by the person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way;
|
• |
it is cast by the Chairman as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the Chairman to vote on the resolution as the Chairman decides; or
|
• |
it is cast by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
|
o |
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on the resolution; and
|
o |
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
|
6. |
Approval of Grant of Performance Rights to James D. Calaway
|
• |
it is cast in favour of a resolution by the person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way;
|
• |
it is cast by the Chairman as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the Chairman to vote on the resolution as the Chairman decides; or
|
• |
it is cast by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
|
o |
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on the resolution; and
|
o |
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
|
(a) |
discuss the Annual Report;
|
(b) |
direct questions or comment on the management of the Company to the Chairman; and
|
(c) |
direct questions to the auditor regarding:
|
a. |
the preparation and the content of the Auditor's Report;
|
b. |
the conduct of the audit;
|
c. |
the accounting policies adopted by the Company in relation to the preparation of the financial statements; and
|
d. |
the independence of the auditor in relation to the conduct of the audit.
|
• |
the preparation and the content of the Auditor's Report;
|
• |
the conduct of the audit;
|
• |
the accounting policies adopted by the Company in relation to the preparation of the financial statements; and
|
• |
the independence of the auditor in relation to the conduct of the audit.
|
(a) |
one third of the Directors (or the nearest whole number); and
|
(b) |
any Director who has held office without re-election past the third annual general meeting,
|
(a) |
Rose McKinney-James retires as a Non-Executive Director at the AGM. Being eligible, Rose McKinney-James offers herself for re-election as a Non-Executive Director; and
|
(b) |
Margaret R. Walker retires as a Non-Executive Director at the AGM. Being eligible, Margaret R. Walker offers herself for re-election as a Non-Executive Director.
|
Name of persons proposed to
receive performance rights:
|
Resolution 4(a) – James D. Calaway (Executive Director, Chairman and related party), or his nominee.
Resolution 4(b) – Alan Davies (Independent Non-Executive Director and related party), or his nominee.
Resolution 4(c) – Stephen Gardiner (Independent Non-Executive Director and related party), or his nominee.
Resolution 4(d) – Rose McKinney-James (Independent Non-Executive Director and related party), or her nominee.
Resolution 4(e) – Margaret R. Walker (Independent Non-Executive Director and related party), or her nominee.
|
|
Formula for calculating the
number of securities to be
issued to persons listed above:
|
The number of Performance Rights to be issued to each Non-Executive Director is equal to the value of 27.7% of the total Non-Executive Director fees payable to the Director divided by the 10-day
Value-Weighted Average Price (VWAP) adjusted by the closing exchange rate as at the date of the AGM.
The number of Performance Rights to be issued to the Chairman (Executive-Director) is equal to the value of 18.9% of the total Chairman fees (excluding James D. Calaway's executive remuneration) payable to
the Chairman divided by the 10-day VWAP as at the date of the AGM.
For example, if the 10-day VWAP as at the date of the AGM is AUD0.337 and the AUD:USD exchange rate is AUD0.664, each Director would receive the number of Performance Rights set out below.
|
Name
|
Value of Performance
Rights
|
Number of
Performance Rights
|
||
James D. Calaway
|
USD35,000
|
156,189
|
||
Alan Davies
|
USD25,000
|
111,563
|
||
Stephen Gardiner
|
USD25,000
|
111,563
|
||
Rose McKinney-James
|
USD25,000
|
111,563
|
||
Margaret R. Walker
|
USD25,000
|
111,563
|
||
Assuming a 10-day VWAP of AUD0.337 and an FX rate of AUD0.69, the total number of Performance Rights to be issued to the Directors would be 602,443, which would amount to 0.0001% of the total number of Shares on issue as at the date of
this Explanatory Memorandum.
|
Date by which the securities
will be issued (Issue Date):
|
If Shareholder approval is obtained, the Performance Rights to be issued to Directors (or their nominees) will be issued on a date no later than one month after the date of the 2023 AGM, as required by ASX
Listing Rule 10.13.5, unless otherwise extended by way of ASX granting a waiver to the Listing Rules.
|
|
Issue price:
|
The issue price will be determined at a price equal to the VWAP for the Company's Shares over the 10 Trading Days immediately before the date of the 2023 AGM.
|
|
Terms of the equity securities:
|
The Performance Rights will be issued at a price equal to the VWAP for the Company's Shares over the 10 Trading Days immediately before the date of the 2023 AGM.
The Performance Rights will vest 12 months after the date of issuance.
On vesting, Directors will be entitled to be allocated one fully paid ordinary share in the Company for each vested Performance Right.
|
|
Purpose of issue:
|
Performance Rights are issued in lieu of paying Directors’ remuneration in cash.
|
|
Details of the Directors' current
remuneration package:
|
Name
|
Total remuneration package
|
|
James D. Calaway:
|
USD497,000(1)
|
||
Alan Davies:
|
USD90,000
|
||
Stephen Gardiner:
|
USD90,000
|
||
Rose McKinney-James:
|
USD90,000
|
||
Margaret R. Walker:
|
USD90,000
|
||
(1) James D. Calaway's total fixed remuneration package consists of USD185,000 in remuneration for his role as Chairman of the Company and USD312,000 of executive remuneration. James D.
Calaway is also eligible to participate in the Equity Incentive Plan in respect of short and Long-Term Incentives (LTI).
Directors’ fees are set in USD – the Chairman's fees being USD185,000 and Independent Non-Executive Directors each being USD90,000 which includes USD5,000 for each of the respective chairs of the Board
Committees. The Chairman, as an Executive Director of the Company also receives USD312,000 in executive remuneration.
The above total remuneration package assumes the award of USD25,000 of Performance Rights to all Independent Non-Executive Directors and an award of USD35,000 in Performance Rights to the Chairman.
|
|||
Price or other consideration for
issue
|
Nil – the Performance Rights will be issued in lieu of paying Directors' remuneration in cash.
|
|
Material terms
|
Other than those terms set out in this Explanatory Memorandum, including that the Performance Rights are issued in lieu of paying Directors' remuneration in cash, there are no other material terms in
relation to the issue.
|
Voting exclusion statement:
|
A voting exclusion statement is contained on page 4 of this Notice of Meeting. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.
|
(a) |
James D. Calaway in relation to Resolution 4(a) because of his interest in that resolution;
|
(b) |
Alan Davies in relation to Resolution 4(b) because of his interest in that resolution;
|
(c) |
Stephen Gardiner in relation to Resolution 4(c) because of his interest in that resolution;
|
(d) |
Rose McKinney-James in relation to Resolution 4(d) because of her interest in that resolution; and
|
(e) |
Margaret R. Walker in relation to Resolution 4(e) because of her interest in that resolution,
|
Name of the person proposed
to receive performance rights:
|
Bernard Rowe (CEO & Managing Director of the Company), or his nominee.
|
|
Category in which ASX Listing
Rules the person falls within
and why
|
10.14.1 as Bernard Rowe as Managing Director of the Company.
|
|
Number and class of securities
to be issued to the person
|
3,736,218 Performance Rights.
|
|
Ioneer’s compensation
framework
|
ioneer’s executive compensation framework aims to provide for fair, competitive remuneration that aligns potential rewards with the Company’s objectives while being transparent to shareholders. Most of our
people are based in the U.S., driving us to align our remuneration framework with U.S. standards. Typically, this means proportionately less cash and higher equity than the Australian market standard, with some of the equity contingent
on service to make up for the relatively low cash proportion. Performance objectives for STI and equity vesting are set such that achievement would accelerate development during our current pre-production phase for higher shareholder
value. This means that the value of remuneration realised at vesting is highly aligned with the value realised by investors.
|
Details of Bernard Rowe's
current total remuneration
package
|
ioneer’s remuneration framework and executive reward strategy provides a mix of fixed and variable remuneration with a blend of short and long-term incentives. The key elements of the remuneration package
for Bernard Rowe is as follows:
• Fixed: Annual base salary of AUD557,400.
• Variable STI: annual cash bonus of up to 80% of base salary.
• Variable LTI: targeted at 120% of base salary.
• Additional employment benefits: superannuation contributions of 11% of base salary.
|
|
Number of securities
previously issued to Bernard
Rowe under the plan and the
average acquisition price (if
any) paid for those securities:
|
Bernard Rowe was issued with:
• 8,893,834 Performance Rights under the Company's Equity Incentive Plan on 16 November 2020 following shareholder approval at the 2020 AGM of the Company;
• 1,350,551 Performance Rights under the Company's Equity Incentive Plan on 5 November 2021 following shareholder approval at the 2021 AGM of the Company; and
• 1,400,209 Performance Rights under the Company's Equity Incentive Plan on 4 November 2022 following shareholder approval at the 2022 AGM of the Company.
The Performance Rights were issued for nil consideration in accordance with the terms of the Equity Incentive Plan.
|
|
Summary of the material terms
of the securities:
|
The Performance Rights will be granted for nil consideration. On vesting, each performance right entitles the holder to be allocated one ordinary share in the Company.
If a vesting condition of a performance right is not achieved by the milestone date, then the performance right will lapse.
|
||||
Grant description
|
Hurdle
|
Vesting date
|
Number
|
||
2023 STI Grant(1)
|
Time-based
|
01/07/24
|
1,753,764
|
||
2023 LTI Grant
|
Time-based
|
01/07/26
|
792,982
|
||
2023 LTI Grant
|
Performance-based
|
01/07/26
|
1,189,472
|
||
Total
|
3,736,218
|
||||
(1) Executive KMP were not paid FY2023 Short-Term Incentives (STIs) in cash. Instead, the Company elected to issue 12-month Performance Rights in lieu of cash payment in order to conserve funds.
In consideration for this delay ioneer has uplifted the STI awarded by an additional 20% in value.
The Board will employ discretion when assessing the vesting of the Performance Rights; below, at or above targets based on the following performance conditions:
• Sustainability Performance: Top quartile HSE & Community performance (North American Mining Projects)
• Construction: Construction delivery compared to schedule as stated at Final Investment Decision (FID)
• Cost Control: Construction spend compared to budget at FID
• Share price: Ioneer share price compared to comparator group
Should Bernard Rowe cease to be employed by the Company prior to the vesting date, the Board may determine at its discretion to vest the Performance Rights on a pro-rated basis, in accordance with the terms of the Equity Incentive Plan
For further information see the Remuneration Report included in the 2023 Annual Report.
|
Explanation of why the type of
security is being used:
|
The purpose of issuing Performance Rights is to provide eligible persons the opportunity to participate in the growth and profits of the Company and to attract, motivate and retain their services to promote
the Company’s long-term success.
|
Value attributed by the
Company to the security and
basis for valuation:
|
Grant description
|
Number of
Performance
Rights
|
Market value
per
Performance
Right
AUD
|
Market value
AUD
|
|
2023 STI Grant
|
1,753,764
|
AUD0.3374
|
AUD591,720
|
||
2023 LTI Grant
|
792,982
|
AUD0.3374
|
AUD267,552
|
||
2023 LTI Grant
|
1,189,472
|
AUD0.3374
|
AUD401,328
|
||
Total
|
3,736,218
|
AUD0.3374
|
AUD1,260,600
|
||
The Market Value per Performance Right is the market value of a fully paid ordinary share in the Company, calculated using a 10-day VWAP, up to and including 30 June 2023. An independent valuation will be obtained should Shareholders
approve this resolution to determine the fair value of the Performance Rights. This fair value may differ from the Market Value shown above.
|
Date on which the securities
will be issued:
|
If Shareholder approval is obtained, as required by ASX Listing Rule 10.15.7, the securities to be issued to Bernard Rowe (or his nominee) will be issued:
(a) in relation to the 2023 STI Grants, on a date which will be no later than one year after the date of the 2023 AGM, unless otherwise extended by way of ASX
granting a waiver to the Listing Rules; and
(b) in relation to the 2023 LTI Grants, on a date which will be no later than three years after the date of the 2023 AGM, unless otherwise extended by way of
ASX granting a waiver to the Listing Rules.
|
|
Price at which the securities
will be issued:
|
Nil consideration.
|
|
Summary of the material terms
of the incentive scheme:
|
The key features of the Equity Incentive Plan are as follows:
(a) the Board will determine the number of awards to be granted to eligible persons (or their nominees), the vesting conditions, and expiry date of the awards
in its sole discretion;
(b) the awards are not transferable unless the Board determines otherwise, or the transfer is required by law and provided that the transfer complies with the
Corporations Act; and
(c) subject to the Corporations Act, ASX Listing Rules, and restrictions on reducing the rights of a holder of awards, the Board will have the power to amend
the Equity Incentive Plan as it sees fit.
A summary of the Equity Incentive Plan is provided in Annexure A. A copy of the Equity Incentive Plan can be obtained by contacting the Company.
|
|
Summary of the material terms
of any loan made to Bernard
Rowe in relation to the
acquisition:
|
N/A
|
Name of the person proposed
to receive performance rights:
|
James D. Calaway (Chairman of the Board and an Executive Director of the Company), or his nominee.
|
|
Category in which ASX Listing
Rules the person falls within
and why
|
10.14.1 as James D. Calaway as an Executive Director of the Company.
|
|
Number and class of securities
to be issued to the person
|
1,992,077 Performance Rights.
|
|
Ioneer’s compensation
framework
|
ioneer’s executive compensation framework aims to provide for fair, competitive remuneration that aligns potential rewards with the Company’s objectives while being transparent to shareholders. Most of our
people are based in the U.S., driving us to align our remuneration framework with U.S. standards. Typically, this means proportionately less cash and higher equity than the Australian market standard, with some of the equity contingent
on service to make up for the relatively low cash proportion. Performance objectives for STI and equity vesting are set such that achievement would accelerate development during our current pre-production phase for higher shareholder
value. This means that the value of remuneration realised at vesting is highly aligned with the value realised by investors.
|
|
Details of James D. Calaway's
current total remuneration
package
|
ioneer’s remuneration framework and executive reward strategy provides a mix of fixed and variable remuneration with a blend of STIs and LTIs. The key elements of the remuneration package for James D.
Calaway is as follows:
• Fixed: annual Board Chairman remuneration of USD185,000 and executive base salary of USD312,000.
• Variable STI: annual cash bonus of up to 60% of base salary.
• Variable LTI: targeted at 60% of base salary.
|
|
Number of securities
previously issued to James D.
Calaway under the plan and
the average acquisition price
(if any) paid for those
securities:
|
James D. Calaway was issued:
• 1,262,740 Performance Rights under the Company's Equity Incentive Plan on 5 November 2021 following shareholder approval at the 2021 AGM of the Company; and
• 682,194 Performance Rights under the Company's Equity Incentive Plan on 4 November 2022 following shareholder approval at the 2022 AGM of the Company.
The Performance Rights were issued for nil consideration in accordance with the terms of the Equity Incentive Plan.
|
|
Summary of the material terms of the securities:
|
The Performance Rights will be granted for nil consideration. On vesting, each performance right entitles the holder to be issued with one ordinary share in the Company.
If a vesting condition of a performance right is not achieved by the milestone date, then the performance right will lapse.
|
Grant description
|
Hurdle
|
Vesting
date
|
Number
|
||
2023 STI Grant(1)
|
Time-based
|
01/07/24
|
1,156,690
|
||
2023 LTI Grant
|
Time-based
|
01/07/26
|
334,155
|
||
2023 LTI Grant
|
Performance-based
|
01/07/26
|
501,232
|
||
Total
|
1,992,077
|
||||
(1) Executive KMP were not paid FY2023 STIs in cash. Instead, the Company elected to issue 12-month Performance Rights in lieu of cash payment in order to conserve funds. In consideration for this delay Ioneer has uplifted the STI
awarded by an additional 20% in value.
The Board will employ discretion when assessing the vesting of the performance based Performance Rights; below, at or above targets based on the following performance conditions:
• Sustainability Performance: Top quartile HSE & Community performance (North American Mining Projects)
• Construction: Construction delivery compared to schedule as stated at FID
• Cost Control: Construction spend compared to budget at FID
• Share price: ioneer share price compared to comparator group
Should James D. Calaway cease to be employed in an executive position in the Company prior to the vesting date, the Board may determine at its discretion to vest the Performance Rights on a pro-rated basis, in accordance with the terms
of the Equity Incentive Plan.
For further information see the Remuneration Report included in the 2023 Annual Report.
|
Explanation of why the type of
security is being used:
|
The purpose of issuing Performance Rights is to provide eligible persons the opportunity to participate in the growth and profits of the Company and to attract, motivate and retain their services to promote
the Company’s long-term success.
|
|
Value attributed by the
Company to the security and
basis for valuation:
|
Grant
description
|
Number of
Performance
Rights
|
Market value per
Performance Rights
AUD
|
Market value
AUD
|
|
2023 STI Grant
|
1,156,690
|
AUD0.3374
|
AUD390,267
|
||
2023 LTI Grant
|
334,155
|
AUD0.3374
|
AUD112,744
|
||
2023 LTI Grant
|
501,232
|
AUD0.3374
|
AUD169,116
|
||
Total
|
1,992,077
|
AUD0.3374
|
AUD672,127
|
||
The Market Value per Performance Right is the market value of a fully paid ordinary share in the Company, calculated using a 10-day VWAP, up to and including the 30 June 2023. An independent valuation will be obtained should
Shareholders approve this resolution to determine the fair value of the Performance Rights. This fair value may differ from the Market Value shown above.
|
Date on which the securities
will be issued:
|
If Shareholder approval is obtained, as required by ASX Listing Rule 10.15.7, the securities to be issued to James D. Calaway (or his nominee) will be issued:
(a) in relation to the 2023 STI grants, on a date which will be no later than one year after the date of the AGM, unless otherwise extended by way of ASX
granting a waiver to the Listing Rules; and
(b) in relation to the 2023 LTI grants, on a date which will be no later than three years after the date of the AGM, unless otherwise extended by way of ASX
granting a waiver to the Listing Rules.
|
Price at which the securities
will be issued:
|
Nil consideration.
|
|
Summary of the material terms
of the incentive scheme:
|
The key features of the Equity Incentive Plan are as follows:
(a) the Board will determine the number of awards to be granted to eligible persons (or their nominees) and the vesting conditions, expiry date of the awards in its
sole discretion;
(b) the awards are not transferable unless the Board determines otherwise, or the transfer is required by law and provided that the transfer complies with the
Corporations Act; and
(c) subject to the Corporations Act, ASX Listing Rules, and restrictions on reducing the rights of a holder of awards, the Board will have the power to amend
the Equity Incentive Plan as it sees fit.
A summary of the Equity Incentive Plan is provided in Annexure A. A copy of the Equity Incentive Plan can be obtained by contacting the Company.
|
|
Summary of the material terms
of any loan made to James D.
Calaway in relation to the
acquisition:
|
N/A
|
Definitions
|
(a) |
in respect of an Option, on the expiry date; or
|
(b) |
the date the applicable vesting conditions are not met and are no longer able to be met.
|
|
1 Year Ioneer (PK) Chart |
1 Month Ioneer (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions